The Journal of Dermatology

<jats:title>Abstract</jats:title><jats:p>The long‐term complications of coronavirus disease 2019 (COVID‐19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID‐19 infection. Only participants confirmed by real‐time reverse transcription‐polymerase chain reaction tests to have COVID‐19 were enrolled in the COVID‐19 group. The matched cohort without COVID‐19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID‐19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non‐infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID‐19 cohort, even after multivariable adjustment for potential confounders. COVID‐19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.</jats:p>

publication_history

received

accepted

published

National Research Foundation of Korea

Data resource profile: the national health information database of the National Health Insurance Service in South Korea

Int J Epidemiol

Vitiligo following COVID‐19 vaccination and primary infection: a case report and systematic review

Cureus

The long-term complications of coronavirus disease 2019 (COVID-19) continue to cause global concern. This study aimed to estimate the incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection. Only participants confirmed by real-time reverse transcription-polymerase chain reaction tests to have COVID-19 were enrolled in the COVID-19 group. The matched cohort without COVID-19 was enrolled randomly at a ratio of 1:1. The incidence and risk of chronic urticaria, vitiligo, alopecia areata, and herpes zoster were assessed in both groups using univariable and multivariable Cox proportional hazard analyses. A total of 4 976 589 COVID-19 patients (9.58% of the total population of South Korea) and an equivalent number of matched non-infected control subjects were analyzed. Chronic urticaria, vitiligo, alopecia areata, and herpes zoster manifested at higher rates within the COVID-19 cohort, even after multivariable adjustment for potential confounders. COVID-19 may increase the risk of developing chronic urticaria, vitiligo, alopecia areata, and herpes zoster.

Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection: A nationwide population-based study.

Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following <scp>COVID</scp>‐19 infection: A nationwide population‐based study

Epidemiological insights into chronic urticaria, vitiligo, alopecia areata, and herpes zoster following <scp>COVID</scp>‐19 infection: A nationwide population‐based study

Clinical Summary

What was studied

Study limitations

Clinical implications

Related Questions